Hemostemix Inc. (HMTXF)
OTC GREY OTC GREY Primary Summary
Hemostemix Inc. (HMTXF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hemostemix Inc. ever had a stock split?
Hemostemix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Thomas A. Smeenk B.A., BA Hons CEO | OTC GREY Exchange | CA4236943060 ISIN |
| Canada Country | - Employees | - Last Dividend | 30 Dec 2020 Last Split | - IPO Date |
Overview
Hemostemix Inc. is a Calgary-based clinical stage biotechnology company committed to the development, manufacturing, and commercialization of innovative blood-derived stem cell therapies for a variety of medical conditions. Utilizing a patient's own blood as a non-invasive source of therapeutic cells, Hemostemix focuses on pioneering treatments that are both effective and devoid of the complexities associated with traditional stem cell therapies. The company's operations span across Canada and the United States, where it is dedicated to pushing the boundaries of regenerative medicine through its cutting-edge research and clinical trials.
Products and Services
- ACP-01 for Vascular Diseases
- Synergetic Cell Populations
- Neural Cell Precursors
- Cardiomyocyte Cell Precursors
An autologous cell therapy product currently in Phase II clinical trials aimed at treating a wide range of vascular diseases including cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. ACP-01 leverages the healing capabilities of stem cells derived from the patient's own blood, promoting a non-invasive and personalized approach to treatment.
Hemostemix is developing therapeutic products consisting of synergetic cell populations designed to enhance the regenerative capabilities of the body. These cell populations are cultivated to work in harmony, targeting specific ailments and accelerating the body's natural healing processes.
The company is working on deriving neural cell precursors from blood cells. These precursors have the potential to treat neurological conditions by repairing or replacing damaged neurons, thus offering hope for diseases currently considered untreatable.
Cardiomyocyte cell precursors are being developed to aid in the regeneration of heart tissue. This innovative approach could revolutionize the treatment of heart diseases by using the patient's own blood-derived cells to foster natural healing and repair of damaged heart muscle.
